Zealand Pharma shares popped on Friday on positive weight loss results from long-acting amylin analog petrelintide.
Vials on the Wegovy line at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on Friday, March 8, 2024.popped on Friday, notching a record high after an early-stage study of its weight loss drug challenger produced positive results. The company said Thursday that a course of 16 weekly high doses of long-acting amylin analog petrelintide reduced body weight by up to 8.6% on average in the study. A placebo drug led to a body weight decrease of 1.7%.Petrelintide was "judged to be safe and well tolerated at all dose levels," and the results provided "robust support" for its potential as an alternative to GLP-1 receptor agonist-based therapies for weight management, Zealand Pharma said in a release.
Law Law Latest News, Law Law Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: nbcchicago - 🏆 545. / 51 Read more »